J&J and Bavarian Nordic expand production of an Ebola vaccine program

(Reuters) - Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program. J&J said that the vaccine regimen, which was discovered in a research program with the National Institutes of Health, combines a Janssen preventative vaccine with a vaccine from Denmark-based Bavarian Nordic . (Reporting by Supriya Kurane in Bangalore, editing by Louise Heavens)